- Home
- AMRN vs SPXX Comparison
AMRN vs SPXX Comparison
Compare AMRN & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMRN | SPXX |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 314.9M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMRN | SPXX |
|---|---|---|
| Price | $13.71 | $18.02 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 94.8K | 51.3K |
| Earning Date | 10-29-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $13.57 |
| 52 Week High | $20.90 | $16.05 |
Technical Indicators
Market Signals| Indicator | AMRN | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 56.95 |
| Support Level | $13.48 | $17.95 |
| Resistance Level | $14.49 | $18.17 |
| Average True Range (ATR) | 0.64 | 0.21 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 24.66 | 85.99 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.